TREM2 and Alzheimer disease: Moreover, preclinical research continues to shed light on its mechanistic involvement, raising the possibility of targeting TREM2 for therapeutic intervention, as has been explored in AD through multiple approaches: for example, dehydroervatamine has recently been demonstrated as a promising new TREM2 agonist that can attenuate neuroinflammation, [45] while TREM2 agonistic monoclonal antibodies are currently under development [46].